Cargando…

Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury

BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorga...

Descripción completa

Detalles Bibliográficos
Autores principales: Usachov, Valentyn, Urban, Thomas J., Fontana, Robert J., Gross, Annika, Iyer, Sapna, Omary, M. Bishr, Strnad, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545365/
https://www.ncbi.nlm.nih.gov/pubmed/26286715
http://dx.doi.org/10.1186/s12916-015-0418-0
_version_ 1782386746065944576
author Usachov, Valentyn
Urban, Thomas J.
Fontana, Robert J.
Gross, Annika
Iyer, Sapna
Omary, M. Bishr
Strnad, Pavel
author_facet Usachov, Valentyn
Urban, Thomas J.
Fontana, Robert J.
Gross, Annika
Iyer, Sapna
Omary, M. Bishr
Strnad, Pavel
author_sort Usachov, Valentyn
collection PubMed
description BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI). METHODS: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and immune staining. RESULTS: Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network disruption in transfected cells. CONCLUSIONS: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0418-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4545365
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45453652015-08-23 Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury Usachov, Valentyn Urban, Thomas J. Fontana, Robert J. Gross, Annika Iyer, Sapna Omary, M. Bishr Strnad, Pavel BMC Med Research Article BACKGROUND: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF). All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease. The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI). METHODS: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs. Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing. The functional impact of keratin variants was assessed using cell transfection and immune staining. RESULTS: Heterozygous and compound amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects. Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were observed. Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls. Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI. These novel variants also led to keratin network disruption in transfected cells. CONCLUSIONS: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI. Other non-cytoskeleton-disrupting keratin variants did not preferentially associate with DILI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0418-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-19 /pmc/articles/PMC4545365/ /pubmed/26286715 http://dx.doi.org/10.1186/s12916-015-0418-0 Text en © Usachov et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Usachov, Valentyn
Urban, Thomas J.
Fontana, Robert J.
Gross, Annika
Iyer, Sapna
Omary, M. Bishr
Strnad, Pavel
Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title_full Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title_fullStr Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title_full_unstemmed Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title_short Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
title_sort prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545365/
https://www.ncbi.nlm.nih.gov/pubmed/26286715
http://dx.doi.org/10.1186/s12916-015-0418-0
work_keys_str_mv AT usachovvalentyn prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT urbanthomasj prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT fontanarobertj prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT grossannika prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT iyersapna prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT omarymbishr prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT strnadpavel prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury
AT prevalenceofgeneticvariantsofkeratins8and18inpatientswithdruginducedliverinjury